Patrick Burnett Buys Shares at $3.64 – Insider Confidence Signals Temporary Undervaluation at Arcutis Biotherapeutics【News Flash】

Insider Activity at Arcutis Biotherapeutics: What Patrick Burnett’s Recent Deal Signals

Arcutis Biotherapeutics (NASDAQ: ARCUTIS) has once again drawn attention from investors with a new insider transaction by Patrick Burnett, the company’s Executive Vice President and Chief Medical Officer. On August 11, 2026, Burnett bought 8,300 shares at $3.64 per share, adding to a portfolio that now sits at roughly 127 600 shares. This purchase comes just days after he sold 8,300 shares at a weighted average of $26.52 in a separate 4‑form filing, and follows a long history of relatively modest trades that have hovered around the $20‑$30 per‑share range.

The Current Trade in Context

Burnett’s latest buy is small relative to the company’s market cap—about 0.25% of the 12‑month average trading volume—but it is noteworthy because it is executed at a price well below the current market value ($26.28). In an environment where the stock has slipped 2.3% over the week and 3.7% over the month, this indicates a belief that the shares are temporarily undervalued. The fact that the trade was executed through a direct purchase rather than a sale suggests that Burnett is looking to reinforce his position rather than hedge against downside risk.

Investor Takeaway

For investors, the key signal is the alignment of insider sentiment with the stock’s recent decline. Burnett’s buying activity, coupled with his extensive history of selling small blocks, indicates a balanced approach: he is not merely trading for liquidity but appears to be positioning himself for a medium‑term upside. The trade also underscores the company’s relative stability—insiders are not liquidating large blocks that could trigger a sharp price drop, yet they are still active in buying, suggesting confidence in the company’s pipeline and management team.

Patrick Burnett: A Profile

Burnett’s insider history is characterized by regular, incremental transactions rather than large, market‑moving moves. Since mid‑2025, he has bought and sold between 222 and 3,800 shares per filing, with prices ranging from $3.64 to $28.98. The bulk of his trades are in common stock, but he has also exercised stock options (e.g., the 15,000‑share option exercise reported in the August 11 filing). His trading pattern shows a willingness to both lock in gains (e.g., selling shares after they have risen to $26–$28) and accumulate positions when the price dips (e.g., buying at $3.64). This disciplined approach is typical of long‑term executives who maintain a vested interest in the company’s success while complying with regulatory disclosure requirements.

Broader Insider Activity

Arcutis’ insider landscape is active but not overly aggressive. Several other officers, such as Matsuda Masaru and Watanabe Todd, have executed multiple sells in the $20–$30 range, mirroring Burnett’s approach. The overall share ownership among executives remains substantial, with no single insider holding more than a few percent of the outstanding shares. This distribution of ownership helps to mitigate the risk of a single stakeholder driving a sharp move in the stock, while still maintaining a sense of confidence in the company’s long‑term prospects.

Bottom Line

Patrick Burnett’s recent purchase at a discount to the market price is a subtle yet meaningful cue for investors. It reflects an insider belief that Arcutis is trading at a temporary trough, and it signals that the company’s leadership remains committed to its therapeutic pipeline. For those watching the stock, this insider buying, combined with the company’s solid fundamentals—a 52‑week high of $31.77 and a positive year‑to‑date gain of 52.93%—suggests that a moderate upside could be on the horizon, especially if clinical milestones or regulatory approvals materialize in the coming quarters.